VRCA:NASDAQVerrica Pharmaceuticals Inc. Analysis
Data as of 2026-05-09 - not real-time
$7.99
Latest Price
8/10Risk
Risk Level: High
Executive Summary
VRCA is trading around $8 with a 20‑day SMA of $6.66 and a 50‑day SMA of $5.94, keeping the price well above both averages and generating a bullish MACD crossover (MACD line > signal line). The RSI sits at 68, indicating strong upward momentum but approaching overbought territory. Volume is increasing and the stock shows a bullish trend direction, while volatility is exceptionally high at roughly 93% over the past 30 days and beta exceeds 2, underscoring pronounced price swings.
Recent material news highlights the acceptance of a late‑breaking abstract for Phase 2 data on VP‑315, an oncolytic peptide targeting basal cell carcinoma, with results to be presented at the upcoming Society for Investigative Dermatology meeting, providing a potential catalyst for valuation uplift.
Recent material news highlights the acceptance of a late‑breaking abstract for Phase 2 data on VP‑315, an oncolytic peptide targeting basal cell carcinoma, with results to be presented at the upcoming Society for Investigative Dermatology meeting, providing a potential catalyst for valuation uplift.
Market Outlook
Short Term
< 1 yearPositive
Model confidence: 7/10
Key Factors
- Bullish technical setup (price above SMA20/50, positive MACD)
- Upcoming Phase 2 data release could spark short‑term price rally
- Increasing volume supports momentum
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- Strong growth narrative from VP‑315 pipeline
- Analyst price targets imply >90% upside
- Revenue growth of ~14% despite current losses
Long Term
> 3 yearsPositive
Model confidence: 9/10
Key Factors
- Potential commercialization of VP‑315 and YCANTH expands addressable market
- Robust cash position relative to modest debt reduces financing risk
- Long‑term upside tied to successful oncology indications
Key Metrics & Analysis
Financial Health
Revenue Growth1380.20%
Profit Margin-50.27%
P/E Ratio-4.7
ROE-240.36%
ROA-14.74%
Debt/Equity6.59
P/B Ratio5.5
Op. Cash Flow$-17627000
Free Cash Flow$-15459625
Industry P/E26.4
Technical Analysis
TrendBullish
RSI67.7
Support$5.11
Resistance$8.50
MA 20$6.66
MA 50$5.94
MA 200$5.90
MACDBullish
VolumeIncreasing
Fear & Greed Index90.73
Valuation
Target Price$16.50
Upside/Downside106.51%
GradeUndervalued
TypeGrowth
Risk Assessment
Beta2.42
Volatility92.87%
Sector RiskHigh
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.